key: cord-1017663-hjppkd27 authors: Lee, S.; Lim, A.-R.; Kim, M.-J.; Choi, Y. Ji; Kim, J.W.; Park, K.H.; Shin, S.W.; Kim, Y.H. title: Innovative countermeasures can maintain cancer care continuity during the COVID-19 pandemic in Korea date: 2020-07-03 journal: Eur J Cancer DOI: 10.1016/j.ejca.2020.06.021 sha: 12725c42c330220a05145d31a9f78af937593c9d doc_id: 1017663 cord_uid: hjppkd27 BACKGROUND: Even though Korea was known to have the highest number of coronavirus disease 19 (COVID-19) infection in the early phase of the pandemic, Korea was able to successfully flatten the curve in a short period of time without extreme measures. We compared the status of cancer management before and after COVID-19 and analyzed how cancer care continuity was maintained in Korea. PATIENTS AND METHODS: We investigated the medical records on the number of cancer diagnosis, cancer surgery, radiation therapy and scheduled chemotherapy conducted in Korea University Anam Hospital from January 1 to April 30, 2019 and from the same period in 2020. We also collected the data of metastatic cancer patients who were hospitalized due to respiratory disease. RESULTS: 1694 cancer diagnoses were made in the study period of 2019, and 1445 diagnoses in 2020 (decreased by 14.7%); the cancer surgery performed 830 and 800 cases; the set-up for radiation therapy decreased from 185 to 140 cases; the number of systemic chemotherapies for metastatic cancer patients treated in department of medical oncology increased from 2555 to 2878 cases. Among hospitalized patients, emergency center visit, intensive care unit admission, discharge after recovery and death reveal no drastic changes. CONCLUSIONS: Routine cancer care for patients with metastatic cancer has been maintained without significant difference before and after the COVID-19 pandemic. The Korean government’s innovative countermeasures in the early phase of outbreak made it possible for cancer care practitioners to provide cancer patients with regular care under the standard infection control protocol. While the coronavirus disease 2019 (COVID- 19) continues to spread, there is a growing concern over the influence of COVID-19 on patients with cancer. Patients affected by cancer are generally more vulnerable to infections due to coexisting chronic disease, overall poor health status, and systemic immunosuppressive states caused by both cancer and anticancer treatments. As a consequence, cancer patients infected with COVID-19 are likely to face more difficult outcomes than other populations. [1] [2] [3] The case fatality rate reached to 7.2% among cancer patients compared with 2.3% in the general population. [4, 5] As the same time, there is uncertainty concerning the daily practice of cancer care during the COVID-19 pandemic for patients with cancer. In terms of cancer diagnosis, active treatment such as surgery, radiation therapy, scheduled chemotherapy and longitudinal follow-up, oncology specialists face additional challenges, for they need to consider how to balance a delay in cancer diagnosis or treatment against the risk for a potential COVID-19 exposure, mitigate the risks for significant care disruptions associated with social distancing behaviors, and manage the appropriate allocation of limited health care resources in this unprecedented time of health care crisis. [5] Korea is no exception in this global pandemic. As of 30 May 2020, a total of 11,441 confirmed cases with COVID-19 have been reported in South Korea, including 269 deaths, 10,398 recovered individuals released from isolation and 774 patients staying in hospital or non-hospital facility for isolation. 902,901 tests performed, of which 886,603 were concluded; the positive rate (confirmed cases) was 1.3% and the case fatality was 2.35%. [6] Since the very first COVID-19 case was identified in Korea on January 20, 2020, COVID-19 patients increased exponentially peaking at 909 cases a day on February 29. However, the number dropped significantly in the next two weeks to fall below 100 on March 15. Korea was able to flatten the COVID-10 curve in only 20 days without enforcing extreme measures of restricting freedom and movement of the people. In the early stage of the COVID-19 outbreak, the Korean Centers for Disease Control & Prevention (KCDC) actively and speedily performed contact tracing, quarantined the contacted persons, and aggressively diagnosed and isolated the COVID-19 infected patients. Responding promptly to the situation and acting in accordance with the government's COVID-19 policies, many private hospitals accommodated and treated COVID-19 infected patients from regions where the medical facilities were overwhelmed. In the meantime, hospitals managed to keep up with daily practices, and most of the cancer centers across the country were able to maintain cancer care continuity under the organized planning and strategic resource allocation according to the KCDC guidance. [7] We investigated the cancer management status before and after the COVID-19 pandemic in the institutional level and analyzed how cancer care continuity was maintained during the COVID-19 pandemic crisis. We investigated the status of daily practice for cancer patients such as cancer diagnosis, cancer surgery, radiation therapy and scheduled chemotherapy from January 1 to April 30, 2020 in Korea University Anam Hospital. In particular, we compared the hospitalized events of metastatic cancer patients who suffered from respiratory disease and their clinical outcomes from January 1 to April 30, 2019 and the same period in 2020. Respiratory signs and symptoms, when combined with lung cancer diagnosis or lung metastasis, are included in this analysis, whereas the same signs and symptoms were excluded when caused only by cancer itself with no infection. Clinical retrospective data were retrieved from the medical records including demographic and clinical features, laboratory findings, and radiologic images. Two physicians reviewed the data independently. Severe clinical events defined by unscheduled visits during regular therapy, visits emergency center, requiring admission to an intensive care unit (ICU), or death. We compared the number of virus testing assay for influenza B and other respiratory viruses for metastatic cancer patients, and counted the number of COVID-19 testing assay for metastatic cancer patients since January 2020 at which time the COVID-19 diagnostic testing became available. This study was approved by the Ethics Committee of the Korea University Anam Hospital (No. K2020-1119-001). The requirement for informed consent was waived by the Ethics Committee, for this study is a retrospective data analysis which does not access the patient's personal information. We collected the medical records of the patients with cancer diagnosis, receiving cancer surgery, setting-up radiation therapy or receiving scheduled chemotherapy (both outpatient and inpatient), as well as foreign patients coming from abroad for cancer treatment via international health center during the study period (Table 1) The clinical contexts and outcomes of metastatic cancer patients hospitalized due to respiratory complication from January and April 2020 were compared with the data from the same period of 2019 in Since WHO declared COVID-19 a global pandemic, global oncology societies have been struggling with challenges in delivering cancer care and striving to profoundly re-organize oncological care so that hospital visits, admissions, therapy-induced or immune-related complications could be reduced as much as possible without compromising cancer outcomes. [8, 9] Our study shows that cancer diagnosis, cancer surgery and radiation therapy only slightly spearheading the responses to COVID-19 as the nation's primary control tower for disease control and most of the hospitals and academic societies in Korea cooperated closely with the government. [14] [15] [16] Most of the private hospitals have been able to maintain their cancer care continuity because the following four strategies have been successfully implemented; early recognition of the threat and rapid activation of national response protocols initiated by national leadership; [17] rapid establishment of widespread diagnostic capacity; [18, 19] upscaling of preventive measures against community transmission, including contact tracing, quarantine, and isolation; [6, 20] and redesigning triage and treatment systems and mobilizing necessary resources for case management. [7] Korea University Anam Hospital, one of the tertiary hospitals in Korea, has quickly implemented systems to protect patients and medical staffs, including outdoor triage clinics for patients with fever or respiratory symptoms; pre-emptive isolation wards for patients with pneumonia; entrance surveillance using fever checks and questionnaires about respiratory symptoms and travel history; protective programs for high-risk units such as the ICU and heightened COVID-19 surveillance for hospital employees (Figure 4 ). Cancer center staffs especially nursing specialists made a point of calling the patients individually the day before their scheduled appointment to screen any possible symptoms and check recent travel and contact history; they also informed patients that non-urgent hospital visits were not beneficial for patient's well-being or infection control or optimizing hospital capacity during the pandemic. With regard to outpatients for chemotherapy infusion units and patients to be hospitalized, COVID-19 test was performed at hospital entering point, if they were "suspicious cases" or "patients under investigation". After a patient underwent COVID-19 testing at a screening clinic, he or she was sent back home to begin self-isolation until the test results were available, which were usually notified to the patient through their cell phone within 12 hours. All patients who resided in highly infectious areas, such as Daegu and Gyeongsangbuk-do, or who have arrived from overseas or contacted the confirmed patient, could receive outpatient clinic management after 2-week self-isolation and visit to the screening clinic. Once tested negative, patients are then allowed to enter the hospital. Since our institution was designated by the government as a 'COVID-19 Protection Hospital', one of the cancer wards was Figure 4 . New COVID-19 cases and speedy response of Korea government and an individual institution turned into a quarantine ward, which necessarily put a limit on the hospitalization capacity for cancer patients. Some patients from Daegu, however, could not be discharged, because the risk of infection and difficulties in accessing local hospital in their hometown forced them to remain in the hospital. After the designation of 'COVID-19 Protection Hospital', a large portion of our doctors, nurses, and hospital personnel worked beyond their regular duties to serve in turn at the 'fever respiratory center'. With our institution's efforts to operate successfully as an official 'COVID-19 Protection Hospital', almost all cancer patients with scheduled anti-cancer therapy could seek and receive necessary medical care and services in a timely and stable manner, without being much affected by the pandemic. As a result of all these tremendous endeavors, we could maintain high standards of care for patients with cancer without overwhelming current healthcare system capacity, and almost all cancer patients with scheduled anti-cancer therapy were able to receive medical services on track. However, without vaccine and therapeutic medicine, we still need to be cautious in continuing our approach to mitigate the crisis with limited knowledge of COVID-19. We believe the information and insights provided in this study will help improve our understanding of the importance of early intervention and cooperation between public and private sector for public health in a time of the pandemic. Nothing to declare. The authors have declared no conflicts of interest. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Patients with Cancer Appear More Vulnerable to SARS-COV-2: A Multicenter Study during the COVID-19 Outbreak Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention A War on Two Fronts: Cancer Care in the Time of COVID-19 Epidemiology & Case Management Team, Korea Centers for Disease Control & Prevention. Contact Transmission of COVID-19 in South Korea: Novel Investigation Techniques for Tracing Contacts National Response to COVID-19 in the Republic of Korea and Lessons Learned for Other Countries ASCO special report: A guide to cancer care delivery during the COVID-19 pandemic Oncology ESfM: COVID-19 and cancer Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands Impact of the COVID-19 pandemic on the symptomatic diagnosis of cancer: the view from primary care Elective surgeries during the COVID-19 outbreak COVID-19 response and containment strategies in the US, South Korea, and Iceland: Lessons learned and future directions Academic Community's Efforts to Guide the Fight Against Coronavirus Disease 2019 (COVID-19) Epidemic in Korea KCDC Risk Assessments on the Initial Phase of the COVID-19 Outbreak in Korea Covid-19 in South Korea Early diagnosis and rapid isolation: response to COVID-19 outbreak in Korea Preparedness and Rapid Implementation of External Quality Assessment Helped Quickly Increase COVID-19 Testing Capacity in the Republic of Korea Guidelines for Laboratory Diagnosis of Coronavirus Disease 2019 (COVID-19) in Korea Innovative screening tests for COVID-19 in South Korea Routine cancer care has been maintained before and after the COVID-19 pandemic.The Korean government's innovative countermeasures were important.Information provided will help you understand public health in pandemic times.